These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 20132334

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series.
    Ettingshausen CE, Kreuz W.
    Haemophilia; 2010 Jan; 16(1):90-100. PubMed ID: 19878335
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW, Lee SY, Park SK.
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [Abstract] [Full Text] [Related]

  • 25. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
    Hedner U.
    Haemophilia; 2008 Nov; 14 Suppl 6():23-7. PubMed ID: 19134030
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
    Ay Y, Ersin T, Yesim O, Hilkay KT, Dilek I, Gulcihan O, Ahmet K.
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
    [Abstract] [Full Text] [Related]

  • 28. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA.
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [Abstract] [Full Text] [Related]

  • 29. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U, Livnat T, Zivelin A, Kenet G.
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [Abstract] [Full Text] [Related]

  • 30. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD, Neufeld EJ, Blanchette V, Salaj P, Gut RZ, Cooper DL.
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [Abstract] [Full Text] [Related]

  • 31. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA, Brosstad F, Tjønnfjord GE.
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [Abstract] [Full Text] [Related]

  • 32. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
    Astermark J, Rocino A, Von Depka M, Van Den Berg HM, Gringeri A, Mantovani LG, Morado M, Garrido RP, Schiavoni M, Villar A, Windyga J, EHTSB.
    Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.
    Zhou ZY, Hay JW.
    Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208
    [Abstract] [Full Text] [Related]

  • 34. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL, Htrs Investigators.
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [Abstract] [Full Text] [Related]

  • 35. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T, Martinowitz U, Azar-Avivi S, Zivelin A, Brutman-Barazani T, Lubetsky A, Kenet G.
    Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
    [Abstract] [Full Text] [Related]

  • 36. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
    Takedani H, Shima M, Horikoshi Y, Koyama T, Fukutake K, Kuwahara M, Ishiguro N.
    Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
    [Abstract] [Full Text] [Related]

  • 37. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I.
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [Abstract] [Full Text] [Related]

  • 38. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R.
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [Abstract] [Full Text] [Related]

  • 39. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.
    Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J.
    Haemophilia; 2005 May; 11(3):261-9. PubMed ID: 15876272
    [Abstract] [Full Text] [Related]

  • 40. Prevention of arthropathy in haemophilia - intensive on-demand treatment, UK perspective.
    Lee CA.
    Haemophilia; 2008 Nov; 14 Suppl 6():11-5. PubMed ID: 19134027
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.